LÄKEMEDELSVERKET
SWEDISH MEDICAL PRODUCTS AGENCY

Summary Public Assessment Report

Liramed
(liraglutide (synthetic))

SE/H/2346/01/DC

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.lakemedelsverket.se E-mail: registrator@lakemedelsverket.se

Summary Public Assessment Report

Liramed
liraglutide (synthetic)

Solution for injection in pre-filled pen, 6 mg/ml

This is a summary of the public assessment report (PAR) for Liramed. It explains how the assessment was made and why the authorisation was recommended as well as the conditions of use. It is not intended to provide practical advice on how to use the product.

For practical information about the use of the product, patients should read the package leaflet or contact their doctor or pharmacist.

What is Liramed and what is it used for?
The product is a 'hybrid medicine'. This means that it is similar to a reference medicine containing the same active substance.
The reference medicine for the product is Victoza.

This medicine is used on its own if your blood sugar is not properly controlled by diet and exercise alone, and you cannot use metformin (another diabetes medicine).

This medicine is used with other medicines for diabetes when they are not enough to control your blood sugar levels. These may include:

- oral antidiabetics (such as metformin, pioglitazone, sulfonylurea, sodium-glucose cotransporter 2 inhibitor (SGLT2i)) and/or insulin.

How does Liramed work?
This medicine contains the active substance liraglutide. It helps your body reduce your blood sugar level only when blood sugar is too high. It also slows food passage through your stomach and can help prevent heart disease.

How is Liramed used?
The pharmaceutical form is solution in pre-filled pen for injection.

Please read section 3 of the package leaflet for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription in Sweden.

What benefits of Liramed have been shown in studies?
Because the product is a hybrid application of Victoza, clinical studies have been provided for Liramed to show efficacy for the difference of Liramed from the reference product Victoza.

For the full list of side effects, see section 4 of the package leaflet.

Why is Liramed approved?
It was concluded that, in accordance with EU requirements, the product has been shown to have comparable quality and is considered to be bioequivalent to the reference medicine. Therefore, the Swedish Medical Products Agency decided that, as for Victoza, the benefits are greater than its risks and recommended that it can be approved for use.
The Swedish Medical Products Agency decided that the benefits are greater than its risks and recommended that it can be approved for use.

What measures are being taken to ensure the safe and effective use of Liramed?
A risk management plan has been developed to ensure that the product is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well.

For more details, please see the full PAR for Liramed on the following website: MRI - Home.

Other information about Liramed
The full PAR for Liramed can be found on the following website: MRI - Home. For more information about treatment with Liramed, please read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 2026-05.